Previous Statements by WOOF
» VCA Antech's CEO Discusses Q2 2011 Results - Earnings Call Transcript
» VCA Antech CEO Discusses Q3 2010 Results - Earnings Call Transcript
» VCA Antech, Inc. Q2 2010 Earnings Call Transcript
Our earnings and guidance releases are available on our website at investor.vcaantech.com. In addition, an audio file of this conference call will be available on our website for a period of 3 months. I'll now turn the conference over to Mr. Tom Fuller, Chief Financial Officer. Please go ahead, sir.Tomas W. Fuller Thank you, Karen. I think that's actually the hardest part of the call. So good job on that, thank you. Thank you, all, for joining for the us for the third quarter 2011 WOOF earnings call. Today we reported 2011 adjusted fully diluted earnings per share of $0.37 per share, which is flat with adjusted earnings per share in 2010 of $0.37 as well. We did have a very successful refinancing in the quarter and as part of that refinancing, we wrote off $2.7 million of cost for about $0.02 a share, bringing the reported EPS of $0.35 to $0.37 which I said, compares to $0.37 in adjusted basis for the prior year. As expected, that streak, which we acquired on August 9, negatively impacted the quarter by about by $0.005 to $0.01. Qualitatively, I think we did an outstanding quarter. We're seeing great improvement in organic growth rates. Our Hospital same-store sales were plus 1% on a day adjusted basis, which is the first positive we've seen since the third quarter of 2008 and a great improvement from the negative 1.9% in the second quarter of this year. Lab internal growth rate plus 2.2%, which is up from 1.7% growth in the second and the first quarter of this year. So great trend improvement in comps, also did a great job on margins our Hospital operating margins were up to 30 basis points and our Lab operating margins were down slightly 30 basis points due entirely to increased energy cost.
So our operating income was roughly flat. The increases in our operating income in our core Hospital and Lab business was offset by weakness in our Sound-Eklin business as well as the expected losses at Vetstreet. We also had a $2.4 million increase in stock-based compensation expense, which was included in the corporate SG&A line. As a result of that, adjusted net income was roughly flat and as I said, EPS was flat at $0.37 per share on an adjusted basis. So I think given the state of the world, I think we had a terrific quarter and the indicators, comps, margins are moving in a really great direction.Antech Diagnostics, total revenue increased 2.2% to $79 million, all due from internal growth. On that 2.2% revenue growth, operating income was up 1.3% and margins as I said, was down 30 basis points to 35.8%. All coming from increasing energy costs. So absent that, we actually saw margin improve on that 2.2% internal growth. As for the components of the growth, the number of requisitions was up 0.2% to $3,242,000. Average requisition was up 2.0% to $24.36 or 2.2% all-in growth rate. Total requisitions for the quarter was the same number at $3,242,000. I think looking at the improvement in the third quarter compared to the second quarter, most of that did come from volumes which were -- have been negative for the past several quarters, negative 0.5% back in Q2 now, volume 0.2% positive in the current quarter for the 2.2% all-in growth rate. So nice improvement in volumes and trends. Read the rest of this transcript for free on seekingalpha.com